▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3608 by analyst upside · 2026-06-27
GRAL
GRAIL, Inc.
Healthcare · Market Cap $3B · P/E 0x
ANALYST PRICE TARGET
+0.1%
implied upside to consensus target
Current Price $65.92
Consensus Target $66.0
Bull Target $80.0
Bear Target $56.0
Analysts Covering 8
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
5
Hold
3
Sell
0
52-Week Low $29.95
52-Week High $118.84
YTD Return -25.8%
FUNDAMENTALS
Market Cap $3B
P/E Ratio (TTM) N/A
Forward P/E -6.8x
EPS (TTM) $-10.30
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $156M
Profit Margin -253.2%
52-WEEK RANGE
52-Week Low $29.95
52-Week High $118.84
Current Price $65.92
Bear Target $56.0
Bull Target $80.0
● Now $65.92 ● Target $66.0
TRADING DATA
Avg Volume 753K
YTD Return -25.8%
Analyst Count 8
Consensus Buy
Upside to Target +0.1%
Last Updated 2026-06-27

ANALYST SUMMARY

GRAIL, Inc. (GRAL) is currently trading at $65.92 with a Wall Street consensus price target of $66.0, implying potential upside of 0.1% over the next 12 months. 8 analysts currently cover GRAL, with a consensus rating of Buy — 62% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $80.0, while the most cautious has a target of $56.0.

GRAL operates in the Healthcare sector with a market capitalisation of $3B. The stock is down 25.8% year-to-date and is currently trading near the lower end of its 52-week range of $29.95 – $118.84.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ITGR +3.9%
Integer Holdings Corporation
$3B · P/E 23.3x · Buy
AUPH -1.3%
Aurinia Pharmaceuticals Inc.
$2B · P/E 8.0x · Buy
OGN -16.7%
Organon & Co.
$4B · P/E 14.5x · Underperform
CPRX +0.5%
Catalyst Pharmaceuticals, Inc.
$4B · P/E 18.2x · Buy
SEM +0.8%
Select Medical Holdings Corporation
$2B · P/E 15.4x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for GRAL, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Goldman Sachs ● Initiated
Neutral 2026-06-05 Building track record
TD Cowen — Reiterated
Buy → Buy 2026-05-06 Building track record
Piper Sandler — Reiterated
Neutral → Neutral 2026-05-06 14% win rate (7 calls)
Mizuho ● Initiated
Neutral 2026-04-10 Building track record
Piper Sandler ● Initiated
Neutral 2026-04-10 14% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2026-03-30 62% win rate (8 calls)
Morgan Stanley — Reiterated
Equal-Weight → Equal-Weight 2026-02-24 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-02-20 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →